Category: Disease Prevention & Management

The Endocrine Society’s annual meeting, ENDO 2026, concluded its multi-day residency at Chicago’s McCormick Place this past June, marking a pivotal moment in the advancement of hormone research and clinical practice. As one of the world’s premier gatherings for endocrine scientists and healthcare providers, the conference served as a nexus for over 7,000 attendees ranging…

The 2026 annual meeting of the Endocrine Society, known as ENDO 2026, convened in Chicago this past June, marking a pivotal moment for a field that stands at the intersection of a global metabolic crisis and a revolution in pharmacological intervention. Against a backdrop of shifting healthcare economics and fluctuating research budgets, the conference served…

The Endocrine Society is mobilizing its membership to join a broad coalition of scientific organizations, healthcare professionals, and patient advocates in Washington, D.C., for the fourteenth annual Rally for Medical Research Hill Day on September 17. This unified effort seeks to influence federal budget priorities by urging Congress to provide $51.3 billion in funding for…

In a landmark presentation at the ENDO 2026 annual meeting, researchers unveiled findings that suggest semaglutide, a prominent glucagon-like peptide-1 (GLP-1) receptor agonist, may offer significant bone-protective benefits for patients with type 2 diabetes. The study, led by investigators at Stanford University, indicates that individuals taking semaglutide experienced a lower rate of bone fractures compared…

The Endocrine Society has officially named Bradley David Anawalt, MD, as the recipient of the 2026 Outstanding Educator Laureate Award, a prestigious recognition that highlights his transformative impact on medical education and his pioneering contributions to the field of andrology. Dr. Anawalt, a professor and vice chair in the Department of Medicine at the University…

The Endocrine Society has officially announced a multifaceted strategic initiative to combat the global obesity epidemic, marked by the launch of a dedicated Center on Obesity and the publication of a landmark Scientific Statement titled "Obesity Science, Research Gaps and Opportunities in the New Era of Obesity Medicines." This dual-pronged approach aims to consolidate decades…

The Endocrine Society has announced a landmark virtual event scheduled for September 9, marking the formal introduction of its new Center on Obesity and the unveiling of a comprehensive Scientific Statement titled Obesity Science, Research Gaps and Opportunities in the New Era of Obesity Medicines. This initiative represents a strategic pivot for the organization, aiming…

The landscape of oncological and metabolic medicine underwent a significant shift during the final week of August as the U.S. Food and Drug Administration issued two landmark approvals aimed at addressing some of the most persistent challenges in modern healthcare. On August 26, the agency granted approval for Rasonque (daraxonrasib), a first-in-class targeted therapy for…

The landscape of metabolic medicine is undergoing a seismic shift as biotechnology firms move beyond the current generation of appetite-suppressing injectables toward more targeted, tissue-specific interventions. Moonwalk Biosciences, a pioneer in the development of adipose-targeted RNA interference (RNAi) therapeutics, solidified its position in this evolving market on September 8 with the announcement of a $70…

Zerihun Haile-Selassie, CAE, the Chief Financial Officer of the Endocrine Society, has been officially recognized as a 2026 Nonprofit CFO of the Year, a distinction that highlights his significant contributions to the fields of nonprofit management, financial innovation, and operational excellence. Selected specifically in the category for CFOs of large nonprofit associations, Haile-Selassie’s selection follows…